Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3

Zhang Xianqing1; Huang Xiaofeng2; Mu Shijie1; Chen Rui1; An Qunxing1; Xia Aijun1; Wu Daocheng3 1Department of Blood Transfusion; Xijing Hospital; Fourth Military Medical University; Xi’an 710032; China 2Central Laboratory; Fourth Military Medical University; Xi’an 710032; China 3Key Laboratory of Biomedical Information Engineering of Ministry of Education; Xi’an Jiaotong University; Xi’an 710038; China

Your Location：

Home >

Browse articles >

Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3

Updated：2026-03-12

- Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3
- Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3
- 解放军医学杂志（英文版） 2009年24卷第5期页码：274-282
- Affiliations：
- Author bio：
- Funds：
- DOI：
  中图分类号： R737.25
- 纸质出版：2009
- Accepted：
Scan QR Code
Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3[J]. 解放军医学杂志（英文版）, 2009,24(5):274-282.

[1].Inhibitory effect of a new gossypol derivative apogossypolone (ApoG2) on xenograft of human prostate cancer cell line PC-3[J].Journal of Medical Colleges of PLA,2009,24(05):274-282.
Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3[J]. 解放军医学杂志（英文版）, 2009,24(5):274-282. DOI：

[1].Inhibitory effect of a new gossypol derivative apogossypolone (ApoG2) on xenograft of human prostate cancer cell line PC-3[J].Journal of Medical Colleges of PLA,2009,24(05):274-282. DOI：

摘要

Abstract

Objective: To investigate the inhibitory effect of apogossypolone （ApoG2） on prostate cancer cell line PC-3 in vivo

and explore its mechanism. Methods: The models of transplantation tumors in Balb/c nu/nu mice were established via subcutaneous injection of PC-3 cells and the tumor-transplanted mice were divided into 4 groups: control group and three ApoG2 treatment groups

with 10 mice in each group. Volumes of the tumor were estimated every 2 d and the morphology of tumor tissues was observed. Immunohistochemistry was employed to observe the expression of Bcl-2

PCNA

CD31

caspase-3 and caspase-8 in tumor tissues. Results: ApoG2 （2.5 mg/kg-10 mg/kg） given intraperitoneally once a day can obviously inhibit the growth of subcutaneous prostatic carcinoma implant. The tumor volume decreased obviously when the treatment dosage was bigger than 5.0 mg/kg （P<0.01）. Meanwhile

ApoG2 decreased the expression of PCNA and CD31

and enhanced the expression of caspases-3

caspase-8 in tumor tissues. Conclusion: ApoG2 exert an inhibitory effect on prostatic carcinoma possibly by inducing apoptosis and inhibiting tumor angiogenesis.

关键词

Keywords

references

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据